$ABT (Abbott Laboratories)

$ABT {{ '2015-12-11T16:04:37+0000' | timeago}} • Announcement

Pharmaceutical company $ABT said its BoD increased the company's quarterly dividend to $0.26/share from $0.24/share, payable on Feb. 16, 2016, to shareholders of record on Jan. 15, 2016. This will mark the 44th consecutive year the company has increased its dividend payout and 368th consecutive quarterly dividend to be paid by $ABT since 1924.

$ABT {{ '2017-12-15T16:46:17+0000' | timeago}} • Announcement

$ABT increased the company's quarterly common dividend to $0.28 per share from $0.265 per share.  The cash dividend is payable Feb. 15, 2018, to shareholders of record at the close of business on Jan. 12, 2018.

$ABT {{ '2017-10-23T14:32:50+0000' | timeago}} • Announcement

$ABT secured FDA clearance in US for its Insertable Cardiac Monitor (ICM) Confirm Rx, world's first and only smartphone compatible ICM designed to help physicians remotely identify cardiac arrhythmias (CA). Once implanted with a quick, minimally-invasive outpatient procedure Confirm Rx continuously monitors heart rhythms to detect a range of CA.

$ABT {{ '2017-10-20T18:04:31+0000' | timeago}} • Webcast

$ABT stated that regarding Alere, the company expects it to contribute around $475MM to its reported sales in FY17 and forecasts a neutral impact on adjusted EPS for the year. For FY17, $ABT continues to forecast comparable operational sales growth in the mid-single digits.

$ABT {{ '2017-10-20T17:56:19+0000' | timeago}} • Webcast

$ABT continues to anticipate CE Mark for its Alinity molecular diagnostic systems in the coming months and expect to begin the launch of the Alinity instruments in the US in 2018. In nutrition business outside China, the company expects to see soft market conditions across few international markets.

$ABT {{ '2017-10-18T18:04:16+0000' | timeago}} • Announcement

$ABT narrowed its FY17 EPS outlook range, which continues to reflect double-digit growth. The company now expects GAAP EPS to be $0.97-0.99 for FY17, while adjusted diluted EPS is now expected in the range of $2.48-2.50, which represents an increase at the mid-point of the guidance range. For 4Q17, $ABT expects EPS to be $0.28-$0.30.

$ABT {{ '2017-10-18T17:33:26+0000' | timeago}} • Announcement

$ABT swung to profit in 3Q17 on higher device sales and benefits from St. Jude Medical acquisition. Strength in medical devices business helped the company post a profit of $603MM or $0.32 per share from a loss of $329MM or $0.24 per share a year ago. Net sales jumped 28.8% to $6.8Bil, with adjusted EPS climbing 12% to $0.66 per share.

$ABT {{ '2017-10-18T13:13:48+0000' | timeago}} • Infographic

$ABT Abbott Laboratories Earnings AlphaGraphic: Q3 2017 Highlights

$ABT {{ '2017-10-02T12:48:41+0000' | timeago}} • Announcement

$ABT extended tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. at a price of $402 per share. The Offer is being extended to allow additional time for the consummation of the Merger. The offer will now expire on Oct. 3, 2017.

$ABT {{ '2017-09-29T14:25:12+0000' | timeago}} • Announcement

$ABT said it plans to close the acquisition of $ALR on October 3, 2017.  With the addition of $ALR, $ABT will have approx. $7Bil in diagnostics sales worldwide, including approx. $2.5Bil on point of care testing.

$ABT {{ '2017-09-22T12:26:48+0000' | timeago}} • Announcement

$ABT got the FDA nod for magnetic resonance (MR)-conditional labeling for its implantable cardioverter defibrillators (ICD) and associated high voltage leads. The new MR-conditional labeling for the Ellipse ICD allows patients to undergo an MRI scan. Patients implanted with Ellipse device and Durata or Optisure leads can also undergo MRI scans.

$ABT {{ '2017-09-18T12:47:46+0000' | timeago}} • Announcement

$ABT is extending its previously announced tender offer to purchase all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. for $402 per share of Preferred Stock. The offer is being extended to allow additional time for the consummation of the merger, which is a condition to the completion of the offer.

$ABT {{ '2017-09-14T16:50:10+0000' | timeago}} • Announcement

$ABT BoD declared a quarterly common dividend of $0.265 per share. The dividend is payable Nov. 15, 2017, to shareholders of record at the close of business on Oct. 13, 2017.

$ABT {{ '2017-09-01T12:22:31+0000' | timeago}} • Announcement

$ABT said it is extending its tender offer to buy for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere at $402 per share. The offer will now expire on Sept. 15, 2017.

$ABT {{ '2017-08-31T13:43:11+0000' | timeago}} • Announcement

$ABT said the Ministry of Health Labour and Welfare in Japan has granted national reimbursement for the FreeStyle Libre glucose monitoring system effective Sept. 1, 2017. The revolutionary system will be widely available to the more than 1MM Japanese people ages six and above with diabetes, both Type 1 and Type 2, on insulin therapy.

$ABT {{ '2017-08-30T16:14:21+0000' | timeago}} • Announcement

$ABT initiated U.S. pivotal clinical study evaluating safety and effectiveness of modified version of its Amplatzer device designed to correct common congenital heart defect that occurs in about 80,000 pre-term infants in the U.S. each year. Patent ductus arteriosus is a common heart defect, accounting for 5-10% of all congenital heart disease.

$ABT {{ '2017-08-30T16:03:53+0000' | timeago}} • Announcement

$ABT announced regulatory approval in Russia and the Netherlands for a new indication for its oral dydrogesterone medicine. Oral dydrogesterone, which has been used to treat progesterone insufficiency conditions, is now approved in these countries as treatment option to prepare uterus in women who undergo in vitro fertilization (IVF) treatment.

$ABT {{ '2017-08-29T16:14:25+0000' | timeago}} • Announcement

$ABT issued new updates for implanted cardiac devices. $ABT notified physicians of updates to its implantable pacemakers and defibrillators as part of its ongoing commitment to continuously improve patient care. The planned updates are designed to provide new patient management tools and further protection against unauthorized access.

$ABT {{ '2017-08-28T13:50:49+0000' | timeago}} • Announcement

$ABT designed the HeartMate 3 system to take LVAD therapy further. In developing the HeartMate 3 system, the company reduced the system's size while reimagining how blood passes through an LVAD. This system deploys Full MagLev technology to reduce trauma to the blood passing through the pump while optimizing blood flow.

$ABT {{ '2017-08-28T13:35:49+0000' | timeago}} • Announcement

$ABT received U.S. FDA approval for its Full MagLev HeartMate 3 Left Ventricular Assist System (LVAD). The HeartMate 3 system provides a new option for physicians managing advanced heart failure patients in need of short-term hemodynamic support and provides patients living with their device new benefits that embody the evolution of LVAD therapy.

$ABT {{ '2017-08-15T12:37:58+0000' | timeago}} • Announcement

North West London Pathology (NWLP) and $ABT signed a $252MM managed equipment services contract for the supply of all analytical equipment and consumables. This includes $ABT's Alinity ci and Alinity h series diagnostics instruments as well as their professional services and informatics solutions known as AlinIQ.

Recent Transcripts

CNCE (Concert Pharmaceuticals, Inc.)
Thursday, November 9 2017 - 1:30pm
VRML (Vermillion, Inc.)
Wednesday, November 8 2017 - 9:30pm
PCRX (Pacira Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
PTLA (Portola Pharmaceuticals, Inc.)
Monday, November 6 2017 - 9:30pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
LIVN (LivaNova PLC)
Thursday, November 2 2017 - 1:00pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
CRY (CryoLife Inc.)
Tuesday, October 31 2017 - 12:00pm
ABBV (AbbVie Inc.)
Friday, October 27 2017 - 1:00pm
CYTK (Cytokinetics, Incorporated)
Thursday, October 26 2017 - 8:30pm
CELG (Celgene Corporation)
Thursday, October 26 2017 - 1:00pm
INVA (Innoviva, Inc.)
Wednesday, October 25 2017 - 9:00pm
KO (The Coca-Cola Company)
Wednesday, October 25 2017 - 1:00pm
ILMN (Illumina Inc.)
Tuesday, October 24 2017 - 9:00pm
ABAX (Abaxis, Inc.)
Tuesday, October 24 2017 - 8:15pm
BIIB (Biogen Inc.)
Tuesday, October 24 2017 - 12:30pm
PETS (PetMed Express, Inc.)
Monday, October 23 2017 - 12:30pm

AlphaGraphics you may like